TEAMS

LEADERSHIP

Andrew - recent
Andrew Park

Chief Financial Officer

Hazel Cheng, Ph.D.

Chief Operating Officer

Andrew Park, MBA

Chief Financial Officer

Andrew Park, MBA

Chief Financial Officer

Scientific advisory board

Larry Kwak, M.D., Ph.D.

Chairman of
Scientific Advisory Board

Steven Rosen, M.D.

Chief Scientific Officer

Michael Wang, M.D

Professor in the University
of Texas

Andrew Park, MBA

Chief Financial Officer

Board of Directors

Paul Y Song, M.D

Co-Founder & CEO at Fuse Biotherapeutics

Nicolas Hwang

Chief Executive Officer 

Shawn Cho,  R.Ph., MBA

Chief Financial Officer

Andrew - recent
Andrew Park

Chief Financial Officer

Partners

City of Hope

Founded in 1913, City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. PeproMene had licensed the development rights of anti-BAFFR antibodies, BAFFR CAR T cell therapy and BAFF-R BiTE from City of Hope. PeproMene also collaborates with City of Hope to manufacture BAFFR CAR T cells using in its GMP facilities, the Cellular Therapy Production Center and the Center for Biomedicine & Genetics. Currently, BAFFR CAR-T Cells (PMB-CT01) phase 1 clinical trials are being conducted at City of Hope for treating relapsed and refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

Andrew Park

Chief Financial Officer

Andrew Park is a director and the Chief Financial Officer and the Secretary of the Company. He is also the Chief Executive Officer of SC&P Resources, Inc. Mr. Park has over 25 years of experience in investment, M&A, accounting, finance, and auditing. He has served as a director of several companies.
He has since gone on to serve as a director of several companies. In his current role as Chief Financial Officer and Secretary of the Company, Mr. Park is responsible for the financial management of the organization. This includes overseeing the accounting, finance, and tax functions. Additionally, he serves as the Chief Executive Officer of SC&P Resources, Inc.
In his current role as Chief Financial Officer and Secretary of the Company, Mr. Park is responsible for the financial management of the organization. His addition to the team strengthens the company’s ability to provide quality financial management and oversight.

Hazel Cheng, Ph.D.

Chief Operating Officer

Hazel Cheng joined PeproMene Bio in March 2022 as a Chief Operating Officer. Dr. Cheng is a professional immunologist bringing over 25 years of biopharmaceutical experience to PeproMene. Prior to joining PeproMene, Hazel held leadership/management positions at Spectrum Pharmaceutical, NKGen Biotech, AltruBio, and Viva Life Science/Westar Nutrition.

 

Dr. Cheng is a highly experienced and well-respected professional in the field of clinical development, regulatory compliance, clinical operations, program/project/alliance management, and strategic outsourcing planning. She has a wealth of knowledge and experience in the development of therapeutic antibodies, antibody-drug conjugates, small compounds, and NK cell therapy.

 

Dr. Cheng received her PhD in Immunology from the College of Medicine at National Taiwan University. Her research interests include investigating the immunologic basis of human diseases and developing new therapeutic therapies for treating cancers and immune-related disorders. She has published papers in peer-reviewed journals and conferences. Dr. Cheng has played a pivotal role in the early development of many therapeutic programs. She has a proven track record of success in designing and implementing clinical development plans that are both efficient and compliant with regulatory requirements.

Larry Kwak, M.D., Ph.D.

Chairman of
Scientific Advisory Board

As Vice President and Deputy Director for Translational Research & Developmental Therapeutics at City of Hope Comprehensive Cancer Center, as well as the chair of the Scientific Advisory Board at PeproMene Bio, Inc., he began his career as Chief of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute (NCI) in 1992. In 2010 Dr. Kwak was named to the TIME100, one of the world’s 100 most influential people named by TIME magazine, for his 20-year commitment to the science of cancer immunotherapy. In 2016, he was awarded the Ho-Am Prize in Medicine for Inventing disruptive technologies for novel immunotherapies now used for highly successful cancer treatments in man, including the first efficacious personalized lymphoma vaccine.

From 2004-2014 Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at M.D. Anderson Cancer Center in Houston, Texas, where he also held the Justin Distinguished Chair in Leukemia Research. Under his leadership, his department successfully captured multiple large team science grants, including two SPORE grants in Lymphoma and Multiple Myeloma, respectively, from the NCI and a SCOR program project grant awarded by the Leukemia and Lymphoma Society.

Dr. Kwak’s research has focused on the development of new ways to treat cancer by harnessing the power of the immune system. He has made major breakthroughs in the development of cancer vaccines and chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. Overall, more than 500 cancer patients have been treated on clinical trials of four unique therapeutic agents invented by Dr. Kwak.

Steven Rosen, M.D.

Chief Scientific Officer

Steven T. Rosen, MD, FACP, FASCO is a world-renowned cancer researcher and the current provost, chief scientific officer, and director of the Comprehensive Cancer Center and the Beckman Research Institute at City of Hope in Duarte, California. He has made notable contributions to our understanding of cancer biology and has helped develop groundbreaking treatments for the disease.

Dr. Rosen has received numerous awards and accolades for his work, including Northwestern University Medical School’s Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996), recognition from the Woman’s Board of Northwestern Memorial Hospital for Compassionate Care (1996), and Israel Cancer Research Fund, Man of Distinction Award (2011), Lifetime Achievement Award (2015), Best Doctors in Chicago and Los Angeles. American Institute for Medical and Biological Engineering (AIMBE’s) College of Fellows (2017), Association of American Physicians (AAP) (2019), Giant of Cancer Care Award (2021).

Dr. Rosen has made notable contributions to our understanding of cancer biology and has helped develop groundbreaking treatments for the disease. He is a widely respected leader in the cancer community and is committed to improving the lives of those affected by cancer. His work continues to make a significant impact on the lives of patients around the world.

Michael Wang, M.D

Professor in the University of Texas

Michael Wang is the Puddin Clarke endowed professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center. He trained in the laboratories at NIH in Bethesda, MD on the prestigious Fogarty International Fellowship Award. He completed his Fellow in Oncology and in Hematology at the University of Texas MD Anderson Cancer Center.

Dr. Wang has published more than 250 peer-reviewed manuscripts. He is a renowned lymphoma researcher and clinician who has made major contributions to the field of mantle cell lymphoma (MCL). He established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for studying the biology and treatment of mantle cell lymphoma. His clinical research led to the FDA approval of the Bruton’s tyrosine kinase inhibitor, ibrutinib, for MCL treatment (Wang et al., NEJM, 2013), FDA approval of acalabrutinib in MCL (Wang et al, Lancet 2017), FDA approval of CD19 CAR T cell therapy in MCL (Wang et al, NEJM, 2020). He successfully led a 10 year phase 3 trial (Shine) with 183 research sites in 28 countries on frontline therapy in MCL (Wang et al, NEJM, 2022).

Michael is the founding and current director of MD Anderson’s mantle cell lymphoma Program of Excellence. He also serves as the Co-principal investigator of the B-Cell Lymphoma Moon Shot Program at the University of Texas MD Anderson Cancer Center. He is a world-renowned expert in MCL, and his work has had a major impact on the standard of care for this disease.

Paul Y Song, M.D

Co-Founder & CEO at Fuse Biotherapeutics

Dr. Paul Y Song is a radiation oncologist and the co-founder and CEO of Fuse Biotherapeutics, a privately held biotechnology company focused on redirected immunotherapy in cancer. He is currently the Vice Chairman at NKGen Biotech, where he previously served as Chief Medical Officer and oversaw the launch of their US operations, 3 successful IND approvals, and all clinical trials. He graduated with honors from the University of Chicago and received his MD degree from George Washington University.

Dr. Song last practiced full-time at Cedars Sinai Medical Center where he was awarded an ASTRO research fellowship in 1995 for his research in radiation inducible gene therapy. He has also served on the Board of Directors for PeproMene since 2022. As an expert in his field, Dr. Song continues to dedicate his career to developing innovative treatments for cancer patients across the globe. His cutting-edge research and development helped improve the lives of countless people living with this disease.

Nicolas Hwang

Chief Executive Officer 

Nicolas Hwang is a Korean business executive who currently serves as a director of the Company. He is also the Chief Executive Officer of JHCOS Partners, Inc. and was the CIO of Hermes Investment from 2016 to 2019. Mr. Hwang has extensive experience in consulting and advising companies on their plans to go public and be listed on KOSPI and KOSDAQ.

Mr. Hwang obtained his Bachelor of Science in Business Administration from Korea University in 1989. He then went on to gain valuable experience working in various industries including finance, investment, and management before taking on his current role at the Company.

With over 15 years of experience in the financial industry, Mr. Hwang brings attained considerable knowledge and expertise to the Company. His experience will be invaluable as the Company continues to grow and expand its business.

Shawn Cho,  R.Ph., MBA

Chief Financial Officer

Sungho (Shawn) Cho became part of Seven Tree Equity Partners in 2019 and presently holds the position of CEO, overseeing teams and investments in the biotechnology, healthcare, and innovative sectors. Seven Tree Equity Partners specializes in investing in promising biotech ventures worldwide.

Before joining Seven Tree Equity Partners, Shawn contributed to business development initiatives at Hanmi Pharmaceuticals, leading pivotal projects across various transaction types, including licensing and co-development with multinational pharmaceutical companies. He adeptly facilitated numerous forms of business collaboration, introducing diverse technologies through adaptable transaction structures. These technologies encompass groundbreaking large and small molecular drugs spanning multiple therapeutic areas, such as immunology, metabolic diseases, and oncology.

Shawn holds registered pharmacist (R.Ph) licenses in Canada and South Korea, and MBA from Korea University.